fiscal fourth quarter 2026
Filed Oct 26, 2026Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Preliminary LYMPHIR wholesaler unit sales rose 120% sequentially and institutional ordering expanded, but the filing contains no revenue, earnings, cash flow, balance-sheet, or audited financial results.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| LYMPHIR units purchased by U.S. wholesalers for the three months ended September 30, 2026other | 792 units | 120% | – |
| LYMPHIR vials ordered by prescribing centers from wholesalers during the fiscal fourth quarterother | 950 LYMPHIR vials | – | – |
| Institutions that have ordered LYMPHIR as of the date of the releaseother | 54 institutions | – | – |
calendar year-end outlook
- NoteGoal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.
- NoteAs Citius Oncology enters fiscal 2027, management expects growing institutional demand, deeper penetration into academic and community treatment centers, and continued sales growth.
What drove it
- Expanded commercial team reached nationwide coverage in August.
- 950 LYMPHIR vials were ordered by prescribing centers from wholesalers during the fiscal fourth quarter, compared to 926 for the fiscal third quarter.
- As of the date of the release, 54 institutions have ordered LYMPHIR, compared to 44 as of August 14, 2026.
- The Company recognizes revenue when wholesaler orders are fulfilled, based on LYMPHIR units sold to wholesalers, net of estimated gross-to-net adjustments.
- Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies.
Concerns
- The unit information is preliminary and unaudited, based on management's current estimates, and subject to completion of year-end closing procedures and the audit of fiscal 2026 financial statements.
- Actual results may differ, and the Company's independent registered public accounting firm has not audited, reviewed or performed any procedures on the preliminary figures.
- Quarterly shipments may fluctuate based on wholesaler purchasing patterns and inventory levels.
- The Company identified a need for substantial additional funds and the ability to raise additional money to fund operations for at least the next 12 months as a going concern.
- The Company cited its ability to regain compliance with Nasdaq's continued listing standards as a risk.
What to watch
- Fiscal fourth-quarter and fiscal year 2026 results expected in December 2026 with the filing of the Annual Report on Form 10-K.
- Whether preliminary wholesaler unit sales are confirmed following year-end closing procedures and the fiscal 2026 audit.
- Progress toward the goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.
- Whether institutional vial orders translate into fulfilled wholesaler orders and recognized revenue.
Analysis
Citius Oncology reported preliminary commercial operating indicators rather than complete financial results for the fiscal fourth quarter ended September 30, 2026. LYMPHIR units purchased by U.S. wholesalers were 792 units, compared with 360 units for the three months ended June 30, 2026, an increase of 120%. This sequential increase followed nationwide coverage by the expanded commercial team in August and indicates substantially higher wholesaler purchasing in the quarter.
Institutional demand also continued to broaden. Prescribing centers ordered 950 LYMPHIR vials from wholesalers during the fiscal fourth quarter, compared with 926 for the fiscal third quarter. As of the release date, 54 institutions had ordered LYMPHIR, compared with 44 as of August 14, 2026. Management is targeting formulary placement at 100 priority institutions by calendar year-end, making the pace of institutional additions and formulary progress central commercial indicators.
The filing distinguishes the demand metrics from reported revenue. Revenue is recognized when wholesaler orders are fulfilled and is based on LYMPHIR units sold to wholesalers, net of estimated gross-to-net adjustments, rather than institutional vial orders. Accordingly, the reported increase in vial orders and wholesaler unit purchases does not provide a reported revenue figure, gross margin, operating expense, loss, earnings per share, or cash-flow result for the period.
The update remains preliminary and unaudited and is subject to year-end closing procedures and the audit of fiscal 2026 financial statements. Management also notes that quarterly shipments may fluctuate with wholesaler purchasing patterns and inventory levels. The Company expects to report complete fiscal fourth-quarter and fiscal year 2026 results in December 2026 with its Annual Report on Form 10-K. The release identifies substantial additional funding needs, the ability to fund operations for at least the next 12 months as a going concern, and Nasdaq listing compliance as risks alongside commercialization execution.
Management, verbatim
The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers more than doubled as our expanded commercial team reached nationwide coverage in August.
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
We are now more than halfway to our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
As we enter fiscal 2027, we expect the momentum we built in the fourth quarter to carry forward, with growing institutional demand, deeper penetration into academic and community treatment centers, and continued sales growth as LYMPHIR becomes further established in CTCL.
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
Not in the filing
stated, not guessed- GAAP revenue for the fiscal fourth quarter 2026
- GAAP and non-GAAP gross profit and gross margin
- GAAP and non-GAAP operating expenses
- GAAP and non-GAAP operating income or loss
- GAAP and non-GAAP net income or loss
- GAAP and non-GAAP earnings or loss per share
- Prior-year financial comparisons
- Segment revenue and segment profit
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Tax rate
- Quantitative revenue, margin, operating-expense, or tax-rate guidance
- Prior guidance for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.